Zaidel O, Lin HC
he serves as an advisor and hes also an investor
Schizophrenia: A meta-analysis of NAC augmentation in schizophrenia found significant improvements in total PANSS scores and negative symptoms (Yolland et al., Aust N Z J Psychiatry, 2020) [75]
Why dual-pathway targeting is more effective Single pathway limitations: GLP-1 alone eventually plateaus Body compensates over time Weight loss slows after 6-12 months Some people don't respond optimally Dual pathway advantages: Harder for body to compensate Multiple redundant systems targeted Sustained weight loss longer Better for non-responders to single therapy Mechanistic synergy: Amylin + GLP-1 naturally work together Both released after meals normally Physiologic combination Not forcing unnatural state Clinical implications: Patients who plateau on semaglutide benefit from adding cagrilintide Initial combination produces maximum results May prevent or delay weight regain Better long-term outcomes Cagrilintide and semaglutide dosing protocols Proper dosing ensures maximum efficacy with manageable side effects
J Dent Allied Sci 1(2):6366
Seiwerth, S., Milavic, M., Vukojevic, J., Gojkovic, S., Krezic, I., Batelja Vuletic, L., Horvat Pavlov, K., Petrovic, A., Sikiric, S., Vranes, H., Prtoric, A., Zizek, H., Durasin, T., Dobric, I., Staresinic, M., Strbe, S., Knezevic, M., Sola, M., Kokot, A., Sever, M., Lovric, E., Skrtic, A., Boban Blagaic, A., & Sikiric, P
